Gilead Sciences (GILD) Depreciation & Amortization (CF) (2009 - 2026)

Gilead Sciences (GILD) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $93.0 million the latest figure, recorded in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $93.0 million, down 4.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $366.0 million (down 4.69% YoY), and the FY2025 annual result was $370.0 million, down 2.89% from the prior year.
• Depreciation & Amortization (CF) was $93.0 million for Q1 2026 at Gilead Sciences, up from $90.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $98.0 million in Q2 2024 and troughed at $80.0 million in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $89.5 million, with a median of $91.0 million recorded in 2023.
• Year-over-year, Depreciation & Amortization (CF) retreated 7.78% in 2022 and advanced 18.07% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $83.0 million in 2022, then increased by 9.64% to $91.0 million in 2023, then grew by 4.4% to $95.0 million in 2024, then declined by 5.26% to $90.0 million in 2025, then increased by 3.33% to $93.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $93.0 million in Q1 2026, $90.0 million in Q4 2025, and $90.0 million in Q3 2025.